PT  - JOURNAL ARTICLE
AU  - Lindell, Robert B.
AU  - Zhang, Donglan
AU  - Bush, Jenny
AU  - Wallace, Douglas C.
AU  - Rabinowitz, Joshua D.
AU  - Lu, Wenyun
AU  - Wherry, E. John
AU  - Weiss, Scott L.
AU  - Henrickson, Sarah E.
TI  - Impaired Lymphocyte Responses in Pediatric Sepsis Vary by Pathogen Type
AID  - 10.1101/2021.09.15.21263652
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.15.21263652
4099  - http://medrxiv.org/content/early/2021/09/20/2021.09.15.21263652.short
4100  - http://medrxiv.org/content/early/2021/09/20/2021.09.15.21263652.full
AB  - Background Sepsis is the leading cause of death in hospitalized children worldwide. Despite its hypothesized immune-mediated mechanism, targeted immunotherapy for sepsis is not available for clinical use.Objective To determine the association between cytometric, proteomic, bioenergetic, and metabolomic abnormalities and pathogen type in pediatric sepsis.Methods Serial PBMC samples were obtained from 14 sepsis patients (34 samples) and 7 control patients for this pilot study. Flow cytometry was used to define immunophenotype, including T cell subset frequency and activation state, and assess intracellular cytokine production. Global immune dysfunction was assessed by TNF-α production capacity and monocyte HLA-DR expression. Mitochondrial function was assessed by bulk respirometry. Metabolites were measured by liquid chromatography-mass spectrometry. Results were compared by timepoint and pathogen type. For detailed Methods, please see the Methods section in this article’s Online Supplement.Results Sepsis patients were older and had higher illness severity compared to controls; demographics were otherwise similar. Compared to controls, sepsis patients demonstrated global immune dysfunction, loss of peripheral of non-naïve CD4+ T cells, and reduced PBMC mitochondrial function. Metabolomic findings in sepsis patients were most pronounced at sepsis onset and included elevated uridine and 2-dehydrogluconate and depleted citrulline. Loss of peripheral non-naïve CD4+ T cells was associated with immune dysfunction and reduced cytokine production despite increased T cell activation. CD4+ T cell differentiation and corresponding pro- and anti-inflammatory cytokines varied by pathogen.Conclusion Pediatric sepsis patients exhibit a complex, dynamic physiologic state characterized by immunometabolic dysregulation which varies by pathogen type.CLINICAL IMPLICATIONS Comprehensive immune monitoring in critically-ill patients using small-volume samples yields novel insights into diverse T cell responses to pediatric sepsis, which may improve future personalized therapies for these high-risk patients.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe data in this report was derived from a prospective, observational study which does not require registration on ClinicalTrials.gov.Funding StatementFinancial support was provided by the Endowed Chair, Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine. Dr. Lindell is also supported by the Thrasher Research Fund #15351. Dr. Wallace is also supported by NIH grants NS021328, MH108592, and OD010944, U.S. Department of Defense grants W81XWH-16-1-0401 and W81XWH-21-1-0128, (PR202887.e002). Dr. Wherry is also supported by the Parker Institute for Cancer Immunotherapy which supports the cancer immunology program at UPenn, and by NIAID AI155577, AI115712, AI117950, AI108545, AI082630. Dr. Weiss is also supported by NIGMS K23GM110496 and NICHD R01HD102396. Dr. Henrickson is also supported by NIAID K08AI135091, the Burroughs Wellcome Fund CAMS, the Clinical Immunology Society, and the American Academy of Allergy, Asthma, and Immunology.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Children's Hospital of Philadelphia IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to the nature of this research, participants of this study did not agree for their data to be shared publicly, so supporting data is not available.PBMCPeripheral blood mononuclear cellsPIM-2Pediatric Index of Mortality-2PRISM-IIIPediatric Risk of Mortality-IIIPELODPediatric Logistic Organ DysfunctionLPSLipopolysaccharideHLA-DRHuman leukocyte antigen - DR isotypeSRCSpare respiratory capacityPMAPhorbol myristate acetateTh1 cellType 1 CD4+ T helper cellTh2 cellType 1 CD4+ T helper cellTh17 cellType 1 CD4+ T helper cellTfh cellT follicular helper cellTreg cellRegulatory T cellTNF-αTumor necrosis factor αIFN-γInterferon γ